Table 2.
Measurements of renal function at month 6.
| n | Tacrolimus/Sirolimus N = 318 | n | Tacrolimus/MMF N = 316 | |
|---|---|---|---|---|
| Creatinine Clearance (Cockcroft-Gault), mean (SE), mL/min | ||||
| Patients completing the study | 250 | 66.4 (1.4) | 266 | 65.2 (1.3) |
| Patients with month 6 dataa | 289 | 64.6 (1.3) | 289 | 63.7 (1.3) |
| Patients with DGF | 48 | 56.1 (20.0) | 38 | 60.5 (22.9) |
| Patients without DGF | 241 | 66.3 (21.5) | 251 | 64.2 (21.9) |
|
| ||||
| Creatinine Clearance (MDRD-4), mean (SD), mL/min | ||||
| Patients completing the study | 250 | 55.3 (1.2) | 266 | 54.0 (1.2) |
| Patients with month 6 dataa | 289 | 53.9 (1.1) | 289 | 53.0 (1.2) |
|
| ||||
| Serum Creatinine, mean, (SD), μmol/L | ||||
| Patients completing the study | 250 | 133.9 (51.4) | 266 | 137.2 (52.7) |
| Patients with month 6 dataa | 289 | 138.2 (57.7) | 289 | 144.7 (93.7) |
| Patients with DGF | 48 | 169.9 (77.0) | 38 | 151.5 (54.8) |
| Patients without DGF | 241 | 131.9 (51.0) | 251 | 143.7 (98.3) |
FAS
DGF: Delayed graft function. MDRD: Modification of Diet in Renal Disease.
aCompleters and withdrawn patients with available data at 6 months after transplantation.